TABLE 1.

Characteristics of patients with PCNSL

Patient	Age	Gender	Sign and symptoms	MRI finding	IHC	Treatment	Complications of treatment	OS	Final Statues
1	44 years	Female	Weakness in left limbs, urinary incontinency, dysarthria, and paresthesia of the left side of her face	Showed an enhancing mass in the right thalamic region and basal ganglia with mass effect in the right ventricle	–	Four cycles of 4.5 g/m2 MTX plus brain RT with total dose of 36 Gy	Insomnia, headache, decreased appetite	20 months	Live
2	60 years	Female	of headache and decrease in visual acuity	a faint heterogeneous mass with mass effect and edema in the left parietal lobe	CD20, LCA, Ki67+ and CK, CD3, GFAP, chromogranin −	Five cycles of 3 g/m2 MTX and then brain RT with total dose of 43.2 Gy	–	33 months	Live
3	42 years	Male	headache, paresthesia of the right side of his face as well as the right hand		–	Five cycles of 3.5 g/m2 MTX and then brain RT with total dose of 36 Gy	–	14 months	Live
4	60 years	Male	headache and decreased visual acuity of the right eye	a large mass in the left parietal lobe with avid non‐homogenous contrast enhancement	–	Five cycles of 3 g/m2 MTX and then brain RT with total dose of 39.6 Gy	–	33 months	Live
5	55 years	Male	amnesia	an enhancing mass with a solid and cystic component in corpus callosum tail and edema	CD20, LCA+, CK, GFAP−	Five cycles of 3 g/m2 MTX and then brain RT with a total dose of 39.6 Gy	–	26 months	Live
6	54 years	Male	headache and left‐side hemiparesis and seizure	an enhancing mass in his right frontal lobe with mass effect	CD20, LCA+, CK, GFAP−	Five cycles of 3.5 g/m2 MTX and then brain RT with total dose of 36 Gy	Cataract	20 months	Dead
7	63 years	Female	headache, depression, cognitive disorders, and urinary incontinency	abnormal signal changes in the left frontotemporoparietal lobe with a considerable amount of edema and mild mass effect over the midline shifting structure	CD20, LCA+, CK, GFAP−	Four cycles of high‐dose MTX (3 g/m2) chemotherapy	Rise of serum creatinine, oral mucositis, pancytopenia, and death	3 months	Dead a
8	37 years	Female	headache, vertigo, and lower limb paraparesis	two masses accompanied by edema in her cerebellum	CD20, LCA+CK, EMA, CD3, HMB45, NSE −	Six cycles of high‐dose MTX (3.5 g/m2) chemotherapy and then underwent WBI with a total dose of 30.6 Gy	Mild neurocognitive disorders	33 months	Live
9	42 years	Female	amnesia and decrease in visual acuity	two foci with enhancement and edema, one in temproparietooccipital lobe and the other one, in the right ventricle	CD20 +	Six cycles of high‐dose MTX (3 g/m2) chemotherapy and then underwent brain RT with a total dose of 42 Gy		42 months	Live
10	64 years	Female	blurred vision	an enhancing lesion with a size of 3 cm in the right frontal lobe	–	Six cycles of Chemotherapy with 3.5 g/m2 MTX and Rituximab (375 mg/m2), then Rituximab plus cytarabine, and then brain RT with a total dose of 30.6 Gy	Dizziness, Mild neurocognitive disorders	15 months	Live
11	57 years	Female	left‐side hemiparesis and dysarthria	an enhancing mass with extensive edema in the right temporal lobe	CD20, LCA+ CD3, CK GFAP−	Two cycles of 3 g/m2 MTX and then brain RT with total dose of 39.6 Gy, and after those Six cycles of R‐CHOP chemotherapy	Candidiasis of mouth, dizziness, weakness	9 months	Dead

^a During the chemotherapy course due to chemotherapy‐induced pancytopenia.